Dr. Carl LeBel is the Chief Development Officer of Frequency Therapeutics. Prior to joining Frequency, Carl served as Chief Scientific Officer of Otonomy from April 2009 to November 2016. Previously, he served as Executive Director and in a variety of other positions at Amgen, Inc., an American multinational biopharmaceutical company. Prior to his time at Amgen, Carl served as Research Scientist at Alkermes, Inc., a biopharmaceutical company developing innovative medicines to help patients with serious chronic conditions. Earlier, he served as Consultant at Arthur D. Little, Inc., a management and technology consulting firm working across a number of industries. Carl is a scientific fellow of the American Academy of Otolaryngology—Head & Neck Surgery, a full member of the Association for Research in Otolaryngology, and a full member of both the American Association for the Advancement of Science and the Society of Toxicology. Carl received his Bachelor’s degree in chemistry from the University of Detroit and his Ph.D. in Biomedical Sciences/Toxicology from Northeastern University.